The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Considering barriers for implementing DVRd as SoC for multiple myeloma outside of specialist centers
Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, shares that he sees no significant barrier to the adoption of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (DVRd) as a frontline standard-of-care (SoC) treatment for multiple myeloma outside specialist centers. Prof. Sonneveld mentions that the regimen is already included in recently revised guidelines, which will facilitate its widespread use. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I don’t see a problem, to be frank, because this is a regimen of four drugs that are widely available, that are combined, but each of them has been approved for frontline setting. So not only in the transplant-eligible patients, but also in the older patients. So I think it will be readily adopted, and that’s what I see in many countries. It’s in the guidelines...
I don’t see a problem, to be frank, because this is a regimen of four drugs that are widely available, that are combined, but each of them has been approved for frontline setting. So not only in the transplant-eligible patients, but also in the older patients. So I think it will be readily adopted, and that’s what I see in many countries. It’s in the guidelines. The guidelines have been revised recently, ESMO guidelines, or now it’s called EHA-ESMO guidelines, as a standard, and it will be used widely. So I don’t think there is a problem there.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
